Circulation, Vol 85, 2034-2038, Copyright © 1992 by American Heart Association
RA Hegele, MR Freeman, A Langer, PW Connelly and PW Armstrong
BACKGROUND. Lipoprotein(a) [Lp(a)] is a low density lipoprotein-like
particle whose apolipoprotein B (apo B) moiety is disulfide-linked to
apo(a), a plasminogen-like inhibitor of fibrinolysis in vitro. We
hypothesized that plasma concentrations of Lp(a) are acutely affected by
intravenous tissue-type plasminogen activator (t-PA). METHODS AND RESULTS.
Patients with unstable angina were randomized to receive either intravenous
t-PA (n = 15) or placebo (n = 11). Two-way ANOVA using repeated measures
revealed a significant effect of t-PA on concentrations of Lp(a) (p =
0.026). There was a 48% fall in Lp(a) from baseline concentrations in the
t-PA group at 12 hours (p = 0.031) but not at 72 hours. Lp(a) in the
placebo group was unchanged. CONCLUSIONS. We conclude that t-PA produces a
sharp and substantial but reversible reduction in plasma Lp(a). These data
suggest that Lp(a) concentration is not as static in vivo as had been
believed and might be acutely modifiable through some mechanism that
induces its removal from the freely circulating state.
ARTICLES
Acute reduction of lipoprotein(a) by tissue-type plasminogen activator
Division of Endocrinology and Metabolism, St. Michael's Hospital, University of Toronto, Ontario.
This article has been cited by other articles:
![]() |
J. H. Klein, R. A. Hegele, D. G. Hackam, M. L. Koschinsky, M. W. Huff, and J. D. Spence Lipoprotein(a) Is Associated Differentially With Carotid Stenosis, Occlusion, and Total Plaque Area Arterioscler Thromb Vasc Biol, October 1, 2008; 28(10): 1851 - 1856. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1992 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |